References
- Tos M. Frequency of secretory otitis media and histology of the normal middle ear mucosa. Int J Pediatr Otolaryngol 1979; 1: 241–8
- Bernstein J M. Biochemical mediators of inflammation in middle ear effusions. Ann Otol Rhinol Laryngol 1976; Suppl 25: 90–6
- Veltri R W, Sprinkle P M. Secretory otitis media: an immune complex disease. Ann Otol Rhinol Laryngol 1976; Suppl 25: 135–9
- DeMaria T F, Prior R B, Briggs B R, Lim D J, Birck H G. Endotoxin in middle ear effusions from patients with chronic otitis media. J Clin Microbiol 1984; 20: 15–7
- Tos M. Pathogenesis and pathology of chronic secretory otitis media. Ann Otol Rhinol Laryngol 1980; Suppl 68: 91–7
- Shibata K, Kadowaki H, Shimazu M, Tomomatsu K, Inoue K. Accumulation study of oxatomide after repeated administration. NRI Life Science 1985; 13: 223–32
- Suzuki M, Kawauchi H, Mogi G. Immune-mediated otitis media with effusion. Am J Otolaryngol 1988; 9: 199–209
- Hara T, Harada S, Ikenaga T, et al. Safe evaluation of KW-4354(oxatomide). Acute toxicity studies and sub-acute and chronic toxicity studies in rats. Jnp Pharmacol Ther 1984; 2769–840.
- Kurimoto F, Sakurai H. The radio-immunoassay method in the measure of arachidonic acid. Igaku no Ayumi [in Japanese] 1987; 143: 323–5
- Hori F, Kawauchi H, Mogi G. Effect of S-carboxymethlcysteine on the clearance of middle ear effusion. Ann Otol Rhinol Rharyngol 1994; 103: 567–75
- Awouter F, Niemegeers C JE, Van den Berk J. Oxatomide, a new orally active drug which inhibits both the release and the effect of allergic mediators. Experientia 1977; 33: 1657–8
- Takasaka K, Akagi M, Mio M. Inhibitory effects of oxatomide on intracellular Ca mobilization, Ca uptake and histamine release, using rat peritoneal mast cells. Int Arch Allergy Appl Immunol 1987; 83: 348–53
- van Reempts J, De Clerk F, Borgers M. Oxatomide protects against degranulation of rat peritoneal mast cells during in vitro challenge with antigen or compound 48/80. Ultrastructural aspect. Agents and Actions 1981; 11: 177–83
- Kosaka Y, Kawabe H, Ishii A. Oxatomide inhibits the release of bronchostrictor arachidonic acid metabolites (iLTC4 and PGD2) from rat mast cells and guinea pig lung. Agents and Actions 1987; 21: 32–7
- Jackson R T, Waitzman M B, Pickford L. Prostaglandins in human middle ear effusions. Prostaglandins 1975; 10: 365–71
- Jung T TK, Juhn S K. Prostaglandins and other arachidonic acid metabolites in the middle ear fluids. Auris Nasus Larynx 1985; 12: 148–50
- Mogi G, Bernstein J M. Immune mechanisms in otitis media with effusion. Immunology of the ear. Raven Press, New York 1987; 289–95
- Nakata J, Suzuki M, Kawauchi H, Mogi G. Experimental otitis media with effusion induced by middle ear effusion. Laryngoscope 1992; 102: 1037–42
- Berger G, Hawke M, Proops D W, Ranadive N S, Wong D. Histamine levels in middle ear effusions. Acta Otolaryngol(Stockh) 1984; 98: 385–90
- Bernstein J M, Okazaki T, Reisman R E. Prostaglandins in middle ear effusions. Arch Otolaryngol 1976; 102: 257–8
- Brodsky L, Faden H, Bernstein J, et al. Arachidonic acid metabolites in middle ear effusions of children. Ann Otol Rhinol Laryngol 1991; 100: 589–92
- Ueno A, Tanaka K, Katori M. Species difference in increased vascular permeability by synthetic leukotrienes C4 and D4. Prostaglandins 1981; 21: 637–48
- Yamaki K, Noda Y, Takagi K, Satake T. Effect of adrenergic and cholinergic agents and leucotrienes on mucociliary transport force measured by using frog palate. Nagoya J Med Sci 1987; 49: 21–30